FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386032178> ?p ?o ?g. }

• W4386032178 abstract "ABSTRACT People with cystic fibrosis (pwCF) experience a range of persistent gastrointestinal symptoms throughout life. There is evidence indicating interaction between the microbiota and gut pathophysiology in CF. However, there is a paucity of knowledge on the potential effects of CF transmembrane conductance regulator (CFTR) modulator therapies on the gut microbiome. In a pilot study, we investigated the impact of Tezacaftor/Ivacaftor dual combination CFTR modulator therapy on the gut microbiota and metabolomic functioning in pwCF. Fecal samples from 12 pwCF taken at baseline and following placebo or Tezacaftor/Ivacaftor administration were subjected to microbiota sequencing and to targeted metabolomics to assess the short-chain fatty acid (SCFA) composition. Ten healthy matched controls were included as a comparison. Inflammatory calprotectin levels and patient symptoms were also investigated. No significant differences were observed in overall gut microbiota characteristics between any of the study stages, extended also across intestinal inflammation, gut symptoms, and SCFA-targeted metabolomics. However, microbiota and SCFA metabolomic compositions, in pwCF, were significantly different from controls in all study treatment stages. CFTR modulator therapy with Tezacaftor/Ivacaftor had negligible effects on both the gut microbiota and SCFA composition across the course of the study and did not alter toward compositions observed in healthy controls. Future longitudinal CFTR modulator studies will investigate more effective CFTR modulators and should use prolonged sampling periods, to determine whether longer-term changes occur in the CF gut microbiome. IMPORTANCE People with cystic fibrosis (pwCF) experience persistent gastrointestinal (GI) symptoms throughout life. The research question “how can we relieve gastrointestinal symptoms, such as stomach pain, bloating, and nausea?” remains a top priority for clinical research in CF. While CF transmembrane conductance regulator (CFTR) modulator therapies are understood to correct underlying issues of CF disease and increasing the numbers of pwCF are now receiving some form of CFTR modulator treatment. It is not known how these therapies affect the gut microbiome or GI system. In this pilot study, we investigated, for the first time, effects of the dual combination CFTR modulator medicine, Tezacaftor/Ivacaftor. We found it had negligible effects on patient GI symptoms, intestinal inflammation, or gut microbiome composition and functioning. Our findings are important as they fill important knowledge gaps on the relative effectiveness of these widely used treatments. We are now investigating triple combination CFTR modulators with prolonged sampling periods." @default.
• W4386032178 created "2023-08-22" @default.
• W4386032178 creator A5014755332 @default.
• W4386032178 creator A5017456934 @default.
• W4386032178 creator A5018648590 @default.
• W4386032178 creator A5047265929 @default.
• W4386032178 creator A5081128925 @default.
• W4386032178 creator A5083965932 @default.
• W4386032178 creator A5085249995 @default.
• W4386032178 creator A5086295933 @default.
• W4386032178 date "2023-08-21" @default.
• W4386032178 modified "2023-09-25" @default.
• W4386032178 title "Tezacaftor/Ivacaftor therapy has negligible effects on the cystic fibrosis gut microbiome" @default.
• W4386032178 cites W101807314 @default.
• W4386032178 cites W1948266836 @default.
• W4386032178 cites W1986386190 @default.
• W4386032178 cites W1990132665 @default.
• W4386032178 cites W2002703043 @default.
• W4386032178 cites W2003342633 @default.
• W4386032178 cites W2039503253 @default.
• W4386032178 cites W2046081300 @default.
• W4386032178 cites W2047406781 @default.
• W4386032178 cites W2051836609 @default.
• W4386032178 cites W2082578477 @default.
• W4386032178 cites W2083953573 @default.
• W4386032178 cites W2100357321 @default.
• W4386032178 cites W2128933212 @default.
• W4386032178 cites W2135623916 @default.
• W4386032178 cites W2145469804 @default.
• W4386032178 cites W2292347922 @default.
• W4386032178 cites W2345330757 @default.
• W4386032178 cites W2401404581 @default.
• W4386032178 cites W2588639303 @default.
• W4386032178 cites W2595297484 @default.
• W4386032178 cites W2608857718 @default.
• W4386032178 cites W2765420678 @default.
• W4386032178 cites W2809478295 @default.
• W4386032178 cites W2883871657 @default.
• W4386032178 cites W2898601962 @default.
• W4386032178 cites W2904356223 @default.
• W4386032178 cites W2905475552 @default.
• W4386032178 cites W2920936362 @default.
• W4386032178 cites W2950905772 @default.
• W4386032178 cites W2952437732 @default.
• W4386032178 cites W3002179032 @default.
• W4386032178 cites W3008025512 @default.
• W4386032178 cites W3015909347 @default.
• W4386032178 cites W3031637004 @default.
• W4386032178 cites W3046615222 @default.
• W4386032178 cites W3049341660 @default.
• W4386032178 cites W3117499075 @default.
• W4386032178 cites W3133371979 @default.
• W4386032178 cites W3140132982 @default.
• W4386032178 cites W3159885408 @default.
• W4386032178 cites W3178823328 @default.
• W4386032178 cites W3199144869 @default.
• W4386032178 cites W3208650781 @default.
• W4386032178 cites W3213679801 @default.
• W4386032178 cites W4200355041 @default.
• W4386032178 cites W4206308405 @default.
• W4386032178 cites W4224260182 @default.
• W4386032178 cites W4226028773 @default.
• W4386032178 cites W4281686026 @default.
• W4386032178 cites W4283526763 @default.
• W4386032178 cites W4379654017 @default.
• W4386032178 doi "https://doi.org/10.1128/spectrum.01175-23" @default.
• W4386032178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37607068" @default.
• W4386032178 hasPublicationYear "2023" @default.
• W4386032178 type Work @default.
• W4386032178 citedByCount "0" @default.
• W4386032178 crossrefType "journal-article" @default.
• W4386032178 hasAuthorship W4386032178A5014755332 @default.
• W4386032178 hasAuthorship W4386032178A5017456934 @default.
• W4386032178 hasAuthorship W4386032178A5018648590 @default.
• W4386032178 hasAuthorship W4386032178A5047265929 @default.
• W4386032178 hasAuthorship W4386032178A5081128925 @default.
• W4386032178 hasAuthorship W4386032178A5083965932 @default.
• W4386032178 hasAuthorship W4386032178A5085249995 @default.
• W4386032178 hasAuthorship W4386032178A5086295933 @default.
• W4386032178 hasBestOaLocation W43860321781 @default.
• W4386032178 hasConcept C126322002 @default.
• W4386032178 hasConcept C143121216 @default.
• W4386032178 hasConcept C203014093 @default.
• W4386032178 hasConcept C21565614 @default.
• W4386032178 hasConcept C2776502428 @default.
• W4386032178 hasConcept C2776938444 @default.
• W4386032178 hasConcept C2777165150 @default.
• W4386032178 hasConcept C2778428886 @default.
• W4386032178 hasConcept C539455810 @default.
• W4386032178 hasConcept C60644358 @default.
• W4386032178 hasConcept C71924100 @default.
• W4386032178 hasConcept C86803240 @default.
• W4386032178 hasConceptScore W4386032178C126322002 @default.
• W4386032178 hasConceptScore W4386032178C143121216 @default.
• W4386032178 hasConceptScore W4386032178C203014093 @default.
• W4386032178 hasConceptScore W4386032178C21565614 @default.
• W4386032178 hasConceptScore W4386032178C2776502428 @default.
• W4386032178 hasConceptScore W4386032178C2776938444 @default.
• W4386032178 hasConceptScore W4386032178C2777165150 @default.
• W4386032178 hasConceptScore W4386032178C2778428886 @default.

• next